CGenetix develops a disruptive technology for non-invasive diagnosis of transplant rejection, with an initial focus on kidney transplants. Our proprietary molecular assay, easy to implement in clinical practices, quantifies graft-specific methylation signatures in cell-free DNA from blood and urine, eliminating solid biopsy risks. This enables accurate, low-risk patient monitoring and improves clinical follow-up and quality of life.